Large Survey Exclusively Focused on Women’s Male Partners Reveals a
Clear Negative Impact of Menopause on Relationships, Lack of Clarity
About Symptoms and Treatments, and Men’s Willingness to Discuss and
Influence Decisions
BOCA RATON, Fla.--(BUSINESS WIRE)--May 6, 2019--
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's
healthcare company, today announced the presentation of results from the
Men’s Attitude Toward Menopause Survey (MATE), a large study of men’s
understanding of and attitudes related to menopause, at the American
College of Obstetricians and Gynecologists 2019 Annual Meeting. The
data, representing insights collected from 450 men married to and living
with women of menopausal age, uncovered men’s perceptions and attitudes
towards menopause and their role in their partner’s menopausal
transition.
The MATE survey showed that while men are sensitive to the changes
experienced by women during their menopause transition and believe those
changes have a negative impact on their relationships, they are less
aware of the specific menopausal symptoms or opportunities available for
women to get relief from symptoms.
When presented with a list of symptoms that their female partners might
be facing, more than half (54%) recognized that their partner was
experiencing sleeplessness or difficulty sleeping. Additionally, nearly
half reported that their partner was living with a lack of energy (49%),
loss of desire for sexual contact (48%), mood swings (47%) and hot
flashes (46%). When prompted to select an option, only 55% attributed
these symptoms to menopause.
Sixty-three percent of respondents believed their partner’s symptoms had
personally affected them with 77% believing the impact was negative to
themselves and their relationships (56%). These men acknowledged that
symptoms of menopause had a great or negative impact on their partners
as it pertained to love making (65%), mood swings (63%) and romance
(58%). Some men noted that it was upsetting or frustrating to see their
partners going through this transition; however, less than half of
respondents were aware that there are treatment options for menopausal
symptoms.
“TherapeuticsMD recognizes that menopause is not only a
life-transitioning event for women, but also for the men in their
lives,” said TherapeuticsMD Chief Medical Officer Sebastian Mirkin. “The
MATE survey reveals an opportunity to make that transition easier by
helping men better understand symptoms and potential solutions to
support their partners in the management of their menopausal symptoms.”
The presentation will be made available on the Investors & Media section
of the company’s website at www.therapeuticsmd.com.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company,
focused on developing and commercializing novel products exclusively for
women. Our products are designed to address the unique changes and
challenges women experience through the various stages of their lives
with a therapeutic focus in family planning, reproductive health, and
menopause management. The company is committed to advancing the health
of women and championing awareness of their healthcare issues. To learn
more about TherapeuticsMD, please visit www.therapeuticsmd.com
or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain forward-looking
statements. Forward-looking statements may include, but are not limited
to, statements relating to TherapeuticsMD’s objectives, plans and
strategies as well as statements, other than historical facts, that
address activities, events or developments that the company intends,
expects, projects, believes or anticipates will or may occur in the
future. These statements are often characterized by terminology such as
“believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,”
“will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments made in
light of management’s experience and perception of historical trends,
current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements in this press
release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a
result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties, many of which are outside of the company’s
control. Important factors that could cause actual results, developments
and business decisions to differ materially from forward-looking
statements are described in the sections titled “Risk Factors” in the
company’s filings with the Securities and Exchange Commission, including
its most recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as reports on Form 8-K, and include the following: the
company’s ability to maintain or increase sales of its products; the
company’s ability to develop and commercialize IMVEXXY®,
ANNOVERA™, BIJUVA™ and its hormone therapy drug
candidates and obtain additional financing necessary therefor; whether
the company will be able to comply with the covenants and conditions
under its term loan facility; the potential of adverse side effects or
other safety risks that could adversely affect the commercialization of
the company’s current or future approved products or preclude the
approval of the company’s future drug candidates; the length, cost and
uncertain results of future clinical trials; the company’s reliance on
third parties to conduct its manufacturing, research and development and
clinical trials; the availability of reimbursement from government
authorities and health insurance companies for the company’s products;
the impact of product liability lawsuits; the influence of extensive and
costly government regulation; the volatility of the trading price of the
company’s common stock and the concentration of power in its stock
ownership. PDF copies of the company’s historical press releases and
financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005087/en/
Source: TherapeuticsMD, Inc.
Investor Contact
Nichol Ochsner
Vice
President, Investor Relations
561-961-1900, ext. 2088
Nochsner@TherapeuticsMD.com